[go: up one dir, main page]

WO2014140868A3 - Formulations d'inhibiteur de xanthine oxydase - Google Patents

Formulations d'inhibiteur de xanthine oxydase Download PDF

Info

Publication number
WO2014140868A3
WO2014140868A3 PCT/IB2014/001042 IB2014001042W WO2014140868A3 WO 2014140868 A3 WO2014140868 A3 WO 2014140868A3 IB 2014001042 W IB2014001042 W IB 2014001042W WO 2014140868 A3 WO2014140868 A3 WO 2014140868A3
Authority
WO
WIPO (PCT)
Prior art keywords
xanthine oxidase
oxidase inhibitor
inhibitor formulations
compositions
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/001042
Other languages
English (en)
Other versions
WO2014140868A2 (fr
Inventor
Davidoff ALLEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES14764884T priority Critical patent/ES2884123T3/es
Priority to EP14764884.4A priority patent/EP3001814B8/fr
Priority to US14/776,905 priority patent/US11406713B2/en
Priority to EP21174259.8A priority patent/EP3915565B1/fr
Publication of WO2014140868A2 publication Critical patent/WO2014140868A2/fr
Publication of WO2014140868A3 publication Critical patent/WO2014140868A3/fr
Anticipated expiration legal-status Critical
Priority to US17/818,159 priority patent/US20230082788A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions pour un inhibiteur de xanthine oxydase qui présente une solubilité améliorée. Les compositions décrites dans le présent document comprennent un inhibiteur de xanthine oxydase combiné avec une base organique. Les compositions peuvent être utilisées pour traiter une maladie ou un état médical qui comprend des niveaux élevés d'acide urique.
PCT/IB2014/001042 2013-03-15 2014-03-17 Formulations d'inhibiteur de xanthine oxydase Ceased WO2014140868A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES14764884T ES2884123T3 (es) 2013-03-15 2014-03-17 Formulaciones de inhibidores de xantina oxidasa
EP14764884.4A EP3001814B8 (fr) 2013-03-15 2014-03-17 Formulations d'inhibiteur de xanthine oxydase
US14/776,905 US11406713B2 (en) 2013-03-15 2014-03-17 Xanthine oxidase inhibitor formulations
EP21174259.8A EP3915565B1 (fr) 2013-03-15 2014-03-17 Formulations d'inhibiteurs d'oxydase de xanthine
US17/818,159 US20230082788A1 (en) 2013-03-15 2022-08-08 Xanthine oxidase inhibitor formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790414P 2013-03-15 2013-03-15
US61/790,414 2013-03-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,905 A-371-Of-International US11406713B2 (en) 2013-03-15 2014-03-17 Xanthine oxidase inhibitor formulations
US17/818,159 Continuation-In-Part US20230082788A1 (en) 2013-03-15 2022-08-08 Xanthine oxidase inhibitor formulations

Publications (2)

Publication Number Publication Date
WO2014140868A2 WO2014140868A2 (fr) 2014-09-18
WO2014140868A3 true WO2014140868A3 (fr) 2014-12-04

Family

ID=51538209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/001042 Ceased WO2014140868A2 (fr) 2013-03-15 2014-03-17 Formulations d'inhibiteur de xanthine oxydase

Country Status (4)

Country Link
US (1) US11406713B2 (fr)
EP (2) EP3915565B1 (fr)
ES (2) ES3042216T3 (fr)
WO (1) WO2014140868A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6861726B2 (ja) * 2016-11-28 2021-04-21 帝人ファーマ株式会社 糖尿病性腎症の治療薬または予防薬
WO2021186250A2 (fr) * 2020-03-15 2021-09-23 Allen Davidoff Procédés de traitement d'infections virales et des conséquences sur la santé
WO2022124325A1 (fr) * 2020-12-08 2022-06-16 国立大学法人東京大学 Activateur intracellulaire d'atp
WO2023118968A2 (fr) * 2021-12-20 2023-06-29 Xortx Therapeutics, Inc. Compositions et procédés pour le diagnostic, le traitement et la prévention d'une maladie rénale
EP4568704A1 (fr) * 2022-08-08 2025-06-18 XORTX Therapeutics Inc. Formulations d'inhibiteur de xanthine oxydase avec bases organiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
US5661154A (en) * 1988-11-25 1997-08-26 Henning Berlin Gmbh Chemie-Und Pharmawerk Oxypurinol alkali and alkaline earth salts in amorphorous or crystalline form as agents for treating hyperuricaemia and gout
US6569862B1 (en) * 1997-11-07 2003-05-27 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
CA2519126A1 (fr) * 2003-03-17 2004-09-30 Ruey J. Yu Biodisponibilite amelioree et administration amelioree de medicaments acides pharmaceutiques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624205A (en) * 1967-04-25 1971-11-30 Burroughs Wellcome Co Treatment of hyperuricemia in humans
US3689641A (en) * 1970-08-20 1972-09-05 Merck & Co Inc Concentrated water suspension of nutrients
US5211956A (en) * 1988-05-19 1993-05-18 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical compositions containing phytic acid or its salts
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
IT1244501B (it) * 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
US5436258A (en) 1992-09-09 1995-07-25 Eli Lilly And Company Prevention of bone resorption
US20030049840A1 (en) * 1998-10-07 2003-03-13 Demetriou Achilles A. Cell preconditioning and cryopreservation medium
US6544726B1 (en) * 1999-05-05 2003-04-08 Knox Van Dyke KVD solution for transplantable organs
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE60137635D1 (de) 2000-06-28 2009-03-26 Merck & Co Inc Verwendung von allopurinol zur behandlung von bluthochdruck
EP1432410A2 (fr) * 2001-09-25 2004-06-30 Ranbaxy Laboratories, Ltd. Procede de preparation d'une forme posologique a dissolution rapide
US8557831B2 (en) 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
US20060141076A1 (en) * 2004-11-01 2006-06-29 Palu Afa K Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
WO2006083687A1 (fr) * 2005-01-28 2006-08-10 Cardiome Pharma Corp. Sel cristallin d'inhibiteurs de xanthine oxydase
EP1948183B1 (fr) * 2005-10-13 2013-12-18 Duke University Compositions pour le traitement et la prévention de maladies cardiaques et procédés d'utilisation de celles-ci
US20090306625A1 (en) * 2007-03-09 2009-12-10 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases
EP2531200B1 (fr) 2010-02-06 2017-07-12 Grünenthal GmbH Procédé de cristallisation et biodisponibilité
EP2536699A2 (fr) * 2010-02-19 2012-12-26 Cadila Healthcare Limited Sels essentiellement purs de fébuxostat et leurs procédés de préparation
CN102372679A (zh) * 2010-08-27 2012-03-14 北京润德康医药技术有限公司 一种非布司他水溶性衍生物及其制备方法
WO2012098501A1 (fr) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Co-cristaux de fébuxostat
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法
US9580379B2 (en) * 2014-06-09 2017-02-28 Baylor College Of Medicine Xanthine oxidase inhibitors and methods of use
US9636368B2 (en) * 2014-08-22 2017-05-02 Food Industry Research And Development Institute Strain of Lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
US5661154A (en) * 1988-11-25 1997-08-26 Henning Berlin Gmbh Chemie-Und Pharmawerk Oxypurinol alkali and alkaline earth salts in amorphorous or crystalline form as agents for treating hyperuricaemia and gout
US6569862B1 (en) * 1997-11-07 2003-05-27 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
CA2519126A1 (fr) * 2003-03-17 2004-09-30 Ruey J. Yu Biodisponibilite amelioree et administration amelioree de medicaments acides pharmaceutiques

Also Published As

Publication number Publication date
EP3001814A2 (fr) 2016-04-06
EP3915565A3 (fr) 2022-03-16
EP3915565A2 (fr) 2021-12-01
EP3001814A4 (fr) 2017-02-15
US20160038595A1 (en) 2016-02-11
EP3001814B8 (fr) 2021-07-07
US11406713B2 (en) 2022-08-09
EP3001814B1 (fr) 2021-05-19
ES2884123T3 (es) 2021-12-10
ES3042216T3 (en) 2025-11-19
EP3915565B1 (fr) 2025-09-10
WO2014140868A2 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
HK1245247A1 (zh) 溴结构域的抑制剂
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
CL2014003121A1 (es) Formulacion liquida que comprende propilenglicol y un inodilatador, un inhibidor de la enzima convertidora de angiotensina o una combinacion de ambos; proceso para prepararla; kit; y metodo de tratamiento de una enfermedad cardiaca y/o hipertension.
WO2013163190A8 (fr) Inhibiteurs d'adn pk
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
AR081678A1 (es) Metodos y composiciones para administracion intratecal de arisulfatasa a
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EP4364796A3 (fr) Utilisation de linagliptine dans une thérapie antidiabétique cardio- et renoprotectrice
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
HK1251566A1 (zh) 作为hdac1/2抑制剂的呱啶衍生物
PH12017500656A1 (en) Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
WO2014140868A3 (fr) Formulations d'inhibiteur de xanthine oxydase
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX383705B (es) Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida.
PL2926867T3 (pl) Kompozycje peelingujące zawierające kwas trichlorooctowy (TCA) i fenol do zmniejszania piekącego bólu wywołanego przez TCA
WO2012040444A3 (fr) Traitement de patients présentant un début de maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14764884

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014764884

Country of ref document: EP